Related Experiment Videos
In vitro predictive testing: the sulfonamide era
International Journal of Cell Cloning
|May 1, 1987
Summary
The human tumor cloning assay accurately predicts chemotherapy response but faces limited clinical use due to past growth challenges and lack of trials. Improved techniques and trial data are emerging, but drug availability remains a key limitation.
Area of Science:
- Oncology
- Clinical Pharmacology
Background:
- The human tumor cloning assay has been used to predict patient response to chemotherapy.
- Over 2,166 clinical correlations have been performed, showing high reliability (69% true positives, 92% true negatives).
Purpose of the Study:
- To review the clinical utility and limitations of the human tumor cloning assay.
- To discuss advancements addressing previous challenges and future prospects.
Main Methods:
- Analysis of clinical correlation data for the human tumor cloning assay.
- Review of improvements in in vitro tumor growth and prospective controlled trials.
Main Results:
- The assay demonstrates high predictive accuracy for chemotherapy response.
- Past limitations included low malignancy growth rates (now 70-80%) and insufficient controlled trials.
- The "sulfonamide era" highlights a lack of potent in vitro agents.
Conclusions:
- Despite high reliability, the cloning assay's clinical adoption is hindered by past technical issues and trial data.
- Improved tumor growth and emerging trial results address previous limitations.
- The availability of more effective in vitro agents is crucial for the assay's future utility.